Related Experiment Video

Updated: Feb 18, 2026

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

14.3K

Network meta-analysis of second-line treatment in metastatic renal cell carcinoma: efficacy and safety

Elie El Rassy1, Fouad Aoun2, Ghassan Sleilaty3

  • 1Department of Medical Oncology, Hotel Dieu de France University Hospital, Faculty of Medicine, Saint Joseph University, Beirut, Lebanon.

Future Oncology (London, England)
|November 30, 2017
PubMed

Insights

The combination of lenvatinib and everolimus is the most effective second-line treatment for metastatic renal cell carcinoma, despite significant side effects. This finding comes from the first network meta-analysis of approved therapies.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Metastatic renal cell carcinoma (mRCC) presents significant treatment challenges.
  • Identifying optimal second-line therapies is crucial for improving patient outcomes.

Purpose of the Study:

  • To compare approved second-line treatment options for metastatic renal cell carcinoma.
  • To evaluate the efficacy and safety of various drug regimens using network meta-analysis.

Main Methods:

  • A frequentist network meta-analysis (NMA) was performed.
  • Generalized pairwise modeling was employed to analyze approved drugs in the second-line setting.

Main Results:

  • The combination of lenvatinib and everolimus demonstrated the lowest hazard ratio (HR) for progression-free survival (HR: 0.4) and overall survival (HR: 0.55).
  • This combination was associated with a high incidence of grade 3-4 adverse events (70.6%), leading to treatment discontinuation in 17.6% of patients.

Conclusions:

  • Lenvatinib plus everolimus shows superior efficacy in second-line treatment for mRCC.
  • The significant toxicity profile necessitates careful patient selection and management.
Keywords:
metastatic renal cell carcinomanetwork meta-analysisoverall survivalprogression-free survivalsecond-linesystematic review

More Related Videos

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy

Published on: April 29, 2014

17.2K
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.9K

Related Concept Videos

Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
784
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K